Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants

被引:43
作者
Gonzalo, RM
Rodríguez, D
García-Sastre, A
Rodríguez, JR
Palese, P
Esteban, M
机构
[1] CSIC, Ctr Nacl Biotecnol, Dept Cellular & Mol Biol, E-28049 Madrid, Spain
[2] CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
influenza and vaccinia virus recombinants; HIV-1; env; CD8(+) cells;
D O I
10.1016/S0264-410X(98)00274-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
With the aim to determine if immunization with two different live recombinant viral vectors could lead to an enhancement of the cellular immune response to HIV-1 antigens, we have characterized the CD8(+) T cell response elicited against the V3 loop epitope from HIV-1 env protein in Balb/c mice immunized with either: a recombinant influenza virus (Flu-Env) expressing the V3 loop epitope from HIV-1 strain IIIB, a vaccinia virus recombinant (VV-Env) expressing the complete HIV-1-IIIB enu protein, or a combination of both. The CD8(+) T cell response, measured by the ELISPOT assay, in animals primed with Flu-Env and boosted with VV-Env was 5 to 6 times higher than in animals inoculated with either Flu-Env or VV-Env alone. Similar results were obtained with recombinant viruses expressing the V3 loop epitope or the complete env protein, respectively, from the MN strain of HIV-1. Our results indicate that the use of two different live vectors for priming and boosting has a synergistic effect on the immune response against HIV-1, and could represent a novel vaccination strategy against AIDS. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:887 / 892
页数:6
相关论文
共 32 条
[1]   Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1 [J].
Berman, PW ;
Murthy, KK ;
Wrin, T ;
Vennari, JC ;
Cobb, EK ;
Eastman, DJ ;
Champe, M ;
Nakamura, GR ;
Davison, D ;
Powell, MF ;
Bussiere, J ;
Francis, DP ;
Matthews, T ;
Gregory, TJ ;
Obijeski, JF .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :52-59
[2]   VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
CAO, YZ ;
QIN, LM ;
ZHANG, LQ ;
SAFRIT, J ;
HO, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) :201-208
[3]   QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE [J].
CARMICHAEL, A ;
JIN, X ;
SISSONS, P ;
BORYSIEWICZ, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :249-256
[4]   Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line [J].
Carroll, MW ;
Moss, B .
VIROLOGY, 1997, 238 (02) :198-211
[5]   LYMPHOCYTE-T PRIMING AND PROTECTION AGAINST FRIEND-LEUKEMIA BY VACCINIA-RETROVIRUS ENV GENE RECOMBINANT [J].
EARL, PL ;
MOSS, B ;
MORRISON, RP ;
WEHRLY, K ;
NISHIO, J ;
CHESEBRO, B .
SCIENCE, 1986, 234 (4777) :728-731
[6]   HIGH-EFFICIENCY FORMATION OF INFLUENZA-VIRUS TRANSFECTANTS [J].
ENAMI, M ;
PALESE, P .
JOURNAL OF VIROLOGY, 1991, 65 (05) :2711-2713
[7]  
ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.immunol.12.1.181
[8]   VACCINE-INDUCED PROTECTION OF CHIMPANZEES AGAINST INFECTION BY A HETEROLOGOUS HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
GIRARD, M ;
MEIGNIER, B ;
BARRESINOUSSI, F ;
KIENY, MP ;
MATTHEWS, T ;
MUCHMORE, E ;
NARA, PL ;
WEI, Q ;
RIMSKY, L ;
WEINHOLD, K ;
FULTZ, PN .
JOURNAL OF VIROLOGY, 1995, 69 (10) :6239-6248
[9]   DRUG-THERAPY - CANDIDATE AIDS VACCINES [J].
GRAHAM, BS ;
WRIGHT, PF .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) :1331-1339
[10]  
JAHAVERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768